Chase Doyle on Muck Rack

Chase Doyle

Los Angeles
As seen in: The ASCO Post, UCLA Newsroom, Modern Medicine, CURE Magazine, OncLive, Urology Times, Pain Medicine News, Oncology Nursing News, Pharmacy Practice News, General Surgery News, American Health & Drug Benefits and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Chase

Contact Chase, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Disease-Free Survival With Gemcitabine Intravesical System in BCG-Unresponsive Papillary-Only Non–Muscle-Invasive Bladder Cancer

|
By Chase Doyle
| The ASCO Post
Monotherapy with a gemcitabine intravesical system (TAR-200; Gem-iDRS) demonstrated high disease-free survival rates in patients with bacillus Calmette-Guérin (BCG)-unresponsive papillary-only high-risk non–muscle-invasive bladder cancer (NMIBC), according to data presented at the 26th Annual Meeting of the Society of Urologic Oncology (SUO).1 Findings from the SunRISe-1 trial showed that TAR-200 appears to be safe and active, signaling a step forward for papillary-only disease (Ta or T1) in...
Open in Who Shared Issue with article?

Intravesical Immunotherapy Shows Recurrence Control in BCG-Unresponsive Papillary-Only Non-Muscle-Invasive Bladder Cancer

|
By Chase Doyle
| The ASCO Post
Intravesical treatment with the investigational immunotherapy cretostimogene grenadenorepvec (CG0070) demonstrated “strong” high-grade recurrence-free survival rates in patients with high-risk, papillary-only, bacillus Calmette-Guérin (BCG)-unresponsive non–muscle-invasive bladder cancer, according to data presented at the 26th Annual Meeting of the Society of Urologic Oncology (SUO).1 Topline results from Cohort P of the multinational, single-arm phase III BOND-003 study showed a 95.7%...
Open in Who Shared Issue with article?

Novel Endocrine Therapy, Giredestrant, Improves Invasive Disease-Free Survival in Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer

|
By Chase Doyle
| The ASCO Post
Giredestrant, a next-generation oral selective estrogen receptor degrader (SERD) and full antagonist, significantly improved invasive disease–free survival as adjuvant treatment for patients with estrogen receptor–positive, HER2-negative early breast cancer compared with standard-of-care endocrine therapy, according to data presented at the 2025 San Antonio Breast Cancer Symposium (SABCS).1 Results from the global, randomized lidERA Breast Cancer trial position giredestrant as a potential new...
Open in Who Shared Issue with article?
See all 591 licensed articles (593 Total)

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Get in touch with Chase

Contact Chase, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified